Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tiziana Life Sciences ( (TLSA) ) just unveiled an update.
On February 21, 2025, Tiziana Life Sciences announced a significant collaboration with Renaissance Lakewood LLC to optimize and scale up the production of intranasal foralumab, a treatment for neurodegenerative and inflammatory diseases. This partnership is crucial for advancing clinical development and potential commercialization, as Renaissance’s expertise in pharmaceutical-nasal product development will ensure high-quality production. Intranasal foralumab is noted for its novel therapeutic approach, aiming to modulate the immune system to reduce neuroinflammation, which is pivotal in conditions like Alzheimer’s and multiple sclerosis.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. They specialize in alternative routes of immunotherapy, with their lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The company’s innovative nasal delivery approach aims to enhance efficacy, safety, and tolerability compared to traditional intravenous methods.
YTD Price Performance: 32.35%
Average Trading Volume: 646,566
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $99.59M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.
